10-QPeriod: Q3 FY2013

AMGEN INC Quarterly Report for Q3 Ended Sep 30, 2013

Filed October 29, 2013For Securities:AMGN

Summary

Amgen Inc. reported solid financial performance for the third quarter of 2013, demonstrating robust revenue and net income growth compared to the prior year. Total revenues increased by 10% year-over-year to $4.75 billion, driven primarily by strong product sales, particularly from key brands like Neulasta/Neupogen, Enbrel, Xgeva, and Prolia. Net income saw a significant jump of 24% to $1.37 billion, resulting in diluted Earnings Per Share (EPS) of $1.79, up from $1.41 in the same period last year. The company highlighted its ongoing strategic initiatives, including continued investment in research and development and the significant acquisition of Onyx Pharmaceuticals completed in early October 2013 for approximately $9.7 billion. This acquisition is expected to bolster Amgen's oncology franchise. Amgen also continues to return capital to shareholders through dividends and has a substantial repurchase program in place, although no shares were repurchased in the second or third quarters of 2013. The company maintains a strong liquidity position, with substantial cash and marketable securities, though it has also increased its long-term debt to finance strategic initiatives.

Financial Highlights

55 data points
Beta

Revenue

$4.75B

81.3% Gross Margin

Net Income

$1.37B

28.8% Net Margin

EPS (Diluted)

$1.79

Total Assets

$57.07B

Cash & Equivalents

$8.28B

Free Cash Flow

$1.63B

Financial Statements
Beta
Revenue$4.75B
Cost of Revenue$788.00M
Gross Profit$3.86B
SG&A Expenses$1.25B
Operating Expenses$3.06B
Operating Income$1.69B
Interest Expense$257.00M
Net Income$1.37B
EPS (Basic)$1.81
EPS (Diluted)$1.79
Shares Outstanding (Basic)754.00M
Shares Outstanding (Diluted)766.00M

Key Highlights

  • 1Total revenues for the third quarter of 2013 increased by 10% to $4.75 billion, with product sales growing 11% year-over-year.
  • 2Net income rose significantly by 24% to $1.37 billion, and diluted EPS increased to $1.79 from $1.41 in the prior year's third quarter.
  • 3Key products like Neulasta/Neupogen, Enbrel, Xgeva, and Prolia showed strong sales growth, contributing significantly to the revenue increase.
  • 4Amgen completed the acquisition of Onyx Pharmaceuticals in early October 2013 for approximately $9.7 billion, significantly expanding its oncology portfolio.
  • 5The company maintained a strong balance sheet with $8.28 billion in cash and cash equivalents and $14.28 billion in marketable securities as of September 30, 2013.
  • 6Amgen continued to return capital to shareholders with a quarterly dividend of $0.47 per share, and had $1.6 billion remaining under its stock repurchase program.
  • 7Research and Development (R&D) expenses increased by 12% to $989 million, reflecting continued investment in pipeline development, including significant costs for evolocumab and the upfront payment for ivabradine rights.

Frequently Asked Questions

Amgen's revenue growth in the third quarter of 2013 was primarily driven by strong performance across its key products, including Neulasta/Neupogen, Enbrel, Xgeva, and Prolia. Overall product sales increased by 11% year-over-year, supported by both unit growth and favorable net sales prices for several of these key drugs.

The acquisition of Onyx Pharmaceuticals, completed on October 1, 2013, for approximately $9.7 billion, is a significant strategic move for Amgen, aimed at strengthening its oncology franchise. While the full financial impact will be detailed in future filings, the transaction was financed through a combination of cash on hand and new debt, increasing Amgen's long-term debt. This acquisition is expected to contribute to future revenue growth and pipeline expansion.

Amgen noted that its material U.S. patents for filgrastim (NEUPOGEN®) were set to expire in December 2013. The company anticipates facing competition in the U.S. market starting in the fourth quarter of 2013, which could materially impact sales of NEUPOGEN® and Neulasta® over time. This is a key factor for investors to monitor going forward.

Amgen maintained a strong liquidity position as of September 30, 2013, with over $22.5 billion in cash, cash equivalents, and marketable securities. The company continues to generate significant cash from operations, which is its primary source of funds. Amgen also utilizes its credit facilities and debt markets to finance its operations and strategic initiatives, including significant debt incurred for the Onyx acquisition. The company is committed to returning capital to shareholders through dividends and has an ongoing stock repurchase program, though it did not repurchase shares in Q2 or Q3 2013.